American BriVision (Holding) Corporation, a clinical-stage biopharmaceutical company, develops drugs and medical devices to meet unmet medical needs in the United States.
| Revenue (TTM) | 797,920 |
| Gross Profit (TTM) | 797,920 |
| EBITDA | $-8.01M |
| Operating Margin | 0.00% |
| Return on Equity | -87.80% |
| Return on Assets | -29.00% |
| Revenue/Share (TTM) | $0.05 |
| Book Value | $0.42 |
| Price-to-Book | 2.78 |
| Price-to-Sales (TTM) | 27.42 |
| EV/Revenue | 40.1 |
| EV/EBITDA | -1.90 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 104.50% |
| Shares Outstanding | $26.00M |
| Float | $20.92M |
| % Insiders | 18.57% |
| % Institutions | 3.14% |
Volatility is currently contracting